200 related articles for article (PubMed ID: 17581297)
1. Bcl-2 downregulation sensitizes nonsmall cell lung cancer cells to cisplatin, but not to docetaxel.
Losert D; Pratscher B; Soutschek J; Geick A; Vornlocher HP; Müller M; Wacheck V
Anticancer Drugs; 2007 Aug; 18(7):755-61. PubMed ID: 17581297
[TBL] [Abstract][Full Text] [Related]
2. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
3. [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs].
Wang JQ; Du ZW; Gao XF; Wu M; Zhang YC; Pan Y; Wang Q; Zhang GZ
Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):191-7. PubMed ID: 23856142
[TBL] [Abstract][Full Text] [Related]
4. Curcumin sensitizes lung cancer cells to cisplatin-induced apoptosis through superoxide anion-mediated Bcl-2 degradation.
Chanvorachote P; Pongrakhananon V; Wannachaiyasit S; Luanpitpong S; Rojanasakul Y; Nimmannit U
Cancer Invest; 2009 Jul; 27(6):624-35. PubMed ID: 19283527
[TBL] [Abstract][Full Text] [Related]
5. The 3p21.3 tumor suppressor RBM5 resensitizes cisplatin-resistant human non-small cell lung cancer cells to cisplatin.
Li P; Wang K; Zhang J; Zhao L; Liang H; Shao C; Sutherland LC
Cancer Epidemiol; 2012 Oct; 36(5):481-9. PubMed ID: 22609235
[TBL] [Abstract][Full Text] [Related]
6. Defects in apoptotic signal transduction in cisplatin-resistant non-small cell lung cancer cells.
Ikuta K; Takemura K; Kihara M; Naito S; Lee E; Shimizu E; Yamauchi A
Oncol Rep; 2005 Jun; 13(6):1229-34. PubMed ID: 15870947
[TBL] [Abstract][Full Text] [Related]
7. MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer.
Chattopadhyay S; Machado-Pinilla R; Manguan-García C; Belda-Iniesta C; Moratilla C; Cejas P; Fresno-Vara JA; de Castro-Carpeño J; Casado E; Nistal M; Gonzalez-Barón M; Perona R
Oncogene; 2006 Jun; 25(23):3335-45. PubMed ID: 16462770
[TBL] [Abstract][Full Text] [Related]
8. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
9. Bcl-2 overexpression enhances in vitro sensitivity against docetaxel in non-small cell lung cancer.
Inoue Y; Gika M; Abiko T; Oyama T; Saitoh Y; Yamazaki H; Nakamura M; Abe Y; Kawamura M; Kobayashi K
Oncol Rep; 2005 Feb; 13(2):259-64. PubMed ID: 15643508
[TBL] [Abstract][Full Text] [Related]
10. Non-receptor tyrosine kinase Etk regulation of drug resistance in small-cell lung cancer.
Guo L; Zhou Y; Sun Y; Zhang F
Eur J Cancer; 2010 Feb; 46(3):636-41. PubMed ID: 20004564
[TBL] [Abstract][Full Text] [Related]
11. miR-503 regulates the resistance of non-small cell lung cancer cells to cisplatin by targeting Bcl-2.
Qiu T; Zhou L; Wang T; Xu J; Wang J; Chen W; Zhou X; Huang Z; Zhu W; Shu Y; Liu P
Int J Mol Med; 2013 Sep; 32(3):593-8. PubMed ID: 23856992
[TBL] [Abstract][Full Text] [Related]
12. Arctigenin enhances chemosensitivity to cisplatin in human nonsmall lung cancer H460 cells through downregulation of survivin expression.
Wang HQ; Jin JJ; Wang J
J Biochem Mol Toxicol; 2014 Jan; 28(1):39-45. PubMed ID: 24395429
[TBL] [Abstract][Full Text] [Related]
13. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
Kastl L; Brown I; Schofield AC
Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
[TBL] [Abstract][Full Text] [Related]
14. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
15. Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation.
Nakano Y; Bilim V; Yuuki K; Muto A; Kato T; Nagaoka A; Tomita Y
Prostate Cancer Prostatic Dis; 2009; 12(1):34-40. PubMed ID: 18475287
[TBL] [Abstract][Full Text] [Related]
16. [Role of Smac in cisplatin-induced apoptosis of non-small cell lung cancer cells].
Cheng XD; Cai SX; Zhao HJ; Li WJ; Tong WC
Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar; 28(3):389-91. PubMed ID: 18359697
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells.
Karabulut B; Erten C; Gul MK; Cengiz E; Karaca B; Kucukzeybek Y; Gorumlu G; Atmaca H; Uzunoglu S; Sanli UA; Baran Y; Uslu R
Cell Biol Int; 2009 Feb; 33(2):239-46. PubMed ID: 19103299
[TBL] [Abstract][Full Text] [Related]
18. [Study of bcl-2 antisense oligodeoxynucleotides on reversal of cisplatin resistance in ovarian cancer cell line A2780/DDP].
Li M; Yu LL; Cai LQ; Wang HB; Wang ZH; Wang ZH
Zhonghua Fu Chan Ke Za Zhi; 2006 Feb; 41(2):121-5. PubMed ID: 16640863
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy of paclitaxel and cisplatin induces apoptosis with Bcl-2 phosphorylation in a cisplatin-resistant human epidermoid carcinoma cell line.
Sawada S; Mese H; Sasaki A; Yoshioka N; Matsumura T
Cancer Chemother Pharmacol; 2003 Jun; 51(6):505-11. PubMed ID: 12709826
[TBL] [Abstract][Full Text] [Related]
20. MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1.
Feng B; Wang R; Chen LB
Cancer Lett; 2012 Apr; 317(2):184-91. PubMed ID: 22120675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
